Breast cancer remains a leading cause of cancer-related mortality among women worldwide, placing an immense burden on global healthcare systems. In early-stage disease, clinicians face the delicate challenge of preventing disease relapse while avoiding systemic overtreatment. Fortunately, multigene expression assays have transformed this clinical landscape by measuring tumor biology rather than relying solely on traditional anatomical indices. These molecular profiling tools quantify gene transcripts to stratify recurrence risks and guide adjuvant therapy. However, clinicians must accurately interpret what these assays can and cannot achieve in daily practice.

Understanding Multigene Expression Assays in Clinical Oncology

Modern clinical practice utilizes five primary multigene platforms: Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, and the Breast Cancer Index. Each diagnostic platform evaluates a unique panel of gene transcripts using distinct laboratory technologies such as real-time quantitative PCR, microarrays, or digital nCounter systems. Consequently, their prognostic scoring algorithms provide complementary yet non-identical clinical outputs.

For instance, Oncotype DX evaluates 21 genes to calculate a Recurrence Score that estimates distant recurrence risk in hormone receptor-positive early breast cancer. In contrast, MammaPrint analyzes a 70-gene profile that dichotomizes tumors into high-risk or low-risk genomic categories. Meanwhile, EndoPredict and Prosigna combine molecular expression signatures with anatomical tumor size and nodal involvement to produce integrated clinical risk scores. Furthermore, Breast Cancer Index quantifies late recurrence risk and predicts benefit from extended endocrine regimens. Although these assays enhance risk stratification, clinicians must remember that each tool was developed and validated in specific clinical cohorts. Therefore, oncologists should never interchange their numerical outputs interchangeably.

Prognostic Versus Predictive Value: Distinguishing Key Capabilities

Clinicians must maintain a strict conceptual distinction between prognostic and predictive biomarkers. A prognostic marker indicates the likely baseline course of disease regardless of future therapy. In contrast, a predictive biomarker specifically forecasts the likelihood of therapeutic benefit from a given systemic intervention.

Importantly, not all commercially available multigene platforms possess validated predictive capabilities. For example, Oncotype DX demonstrated both robust prognostic accuracy and definitive chemotherapy prediction in prospective clinical trials like TAILORx and RxPONDER. Patients with low recurrence scores derive negligible survival benefit from adjuvant cytotoxic regimens, which spares thousands from toxic side effects. Conversely, signatures like Prosigna and EndoPredict primarily offer refined prognostic information across early and late follow-up intervals. Therefore, clinicians must select diagnostic assays according to the exact clinical question at hand. Misinterpreting purely prognostic data as evidence of systemic drug resistance can lead to harmful deviations in adjuvant decision-making.

Axillary Staging Limits: Why Genomic Panels Cannot Replace SLNB

Despite significant advances in molecular oncology, multigene assays cannot determine anatomical axillary lymph node status. Genomic classifiers quantify the intrinsic biological aggressiveness of the primary tumor, but they cannot verify whether metastatic seeds have colonized regional lymph nodes. Consequently, axillary staging still requires clinical palpation, high-resolution ultrasonography, and formal sentinel lymph node biopsy.

Dedicated gene expression signatures designed for nodal metastasis exist, but they derive almost exclusively from retrospective or single-institution cohorts. Because these experimental panels lack prospective validation, international clinical guidelines firmly advise against using genomic scores to guide surgical axillary staging. Instead, current strategies to omit sentinel node biopsy rely entirely on rigorous clinical and radiological trial criteria, such as those established in the SOUND and INSEMA clinical trials. These surgical studies demonstrate that imaging-negative, small tumors can safely forgo surgical axillary dissection in selected elderly or low-risk patients. Therefore, surgeons must never omit sentinel lymph node sampling based purely on a favorable primary tumor multigene profile.

Trial Evidence Across Age and Menopausal Cohorts

Clinical trial data reveal striking differences in assay performance between premenopausal and postmenopausal cohorts. Large prospective evaluations established clear chemotherapy thresholds for postmenopausal women with hormone receptor-positive, node-negative or limited node-positive disease. In these older patients, low genomic risk reliably identifies individuals who can safely omit cytotoxic chemotherapy without compromising disease-free survival.

However, premenopausal women present a far more complex scenario. In trials like TAILORx and RxPONDER, younger women with intermediate genomic scores derived a modest chemotherapy benefit of several percentage points. Notably, oncologists continue to debate whether this outcome reflects true cytotoxic sensitivity or secondary medical castration. Because cytotoxic agents frequently induce premature ovarian failure, the apparent chemotherapy benefit in younger cohorts might stem entirely from systemic estrogen deprivation. Furthermore, most age-stratified outcomes originated from exploratory post hoc subgroup analyses rather than pre-specified primary trial endpoints. Consequently, multidisciplinary tumor boards must interpret these younger-cohort benefits cautiously when weighing ovarian function suppression against cytotoxic regimens.

Emerging Technologies: Circulating Tumor DNA and Multi-Omics

The molecular diagnostics pipeline is moving rapidly beyond static formalin-fixed tumor blocks. Liquid biopsy approaches utilizing circulating tumor DNA (ctDNA) allow serial, non-invasive assessment of minimal residual disease. By detecting microscopic hematogenous shedding before radiological recurrence appears, serial ctDNA tracking enables timely systemic escalation.

Similarly, multi-omics platforms combine whole-transcriptome sequencing, epigenetic methylation patterns, and spatial proteomics to generate comprehensive tumor models. These integrated multi-omics assays illuminate complex resistance pathways, including subclonal alterations that drive endocrine therapy failure. Nevertheless, these cutting-edge molecular diagnostics remain investigational rather than standard care. Clinicians require completed prospective interventional trials demonstrating that ctDNA-directed treatment alterations translate into superior overall survival. Until randomized clinical trials deliver reproducible outcome improvements, tissue-based multigene mRNA panels remain the established standard for adjuvant systemic treatment planning.

Practical Considerations for Oncology Practice in India

Implementing genomic risk stratification in Indian clinical oncology requires careful attention to logistical, financial, and demographic realities. Western multigene tests often involve significant out-of-pocket expenses and require shipping tissue specimens abroad, creating substantial barriers for many families. However, local validation and the emergence of cost-effective indigenous assays, such as CanAssist Breast, offer increasingly viable solutions for resource-conscious settings.

Moreover, breast cancer epidemiology in India differs noticeably from Western cohorts, characterized by an earlier median age of presentation and higher proportions of aggressive, node-positive disease. Therefore, Indian multidisciplinary teams must ensure that genomic profiling matches the precise clinical context of the patient. Clinicians should reserve multigene testing for cases where the result will genuinely sway systemic chemotherapy decisions. By thoughtfully integrating validated genomic assays alongside clinical tumor grade, nodal status, and receptor expression, oncologists can optimize therapeutic efficacy while shielding patients from avoidable toxicity and catastrophic healthcare spending.

Can multigene expression assays replace sentinel node biopsy?

No, multigene expression assays cannot replace surgical sentinel lymph node biopsy. Current assays were developed and validated solely to estimate distant recurrence risk and predict systemic therapy response. Because they cannot reliably confirm or exclude regional lymphatic dissemination, axillary staging still requires clinical examination, radiological imaging, and surgical nodal biopsy. Clinicians must follow validated surgical criteria from trials like SOUND rather than molecular profiles when considering axillary de-escalation.

Which patients derive the most benefit from multigene profiling?

Multigene profiling delivers the highest clinical utility in patients with early-stage, estrogen receptor-positive, HER2-negative invasive breast cancer with uninvolved lymph nodes or limited nodal metastasis. In these ambiguous cases, clinicopathological factors alone often lead to overtreatment. By differentiating low-risk biology from high-risk disease, validated assays identify patients who can safely omit cytotoxic chemotherapy, thereby tailoring systemic management while sparing patients from debilitating toxicities.

How do multigene scores influence extended endocrine decisions?

Certain specialized multigene assays, particularly the Breast Cancer Index, evaluate late distant recurrence risks beyond the initial five years of standard adjuvant endocrine therapy. Furthermore, the assay predicts whether an individual patient will achieve meaningful disease-free survival improvements by continuing hormonal therapy for up to ten years. Clinicians use these molecular insights alongside patient tolerance and bone health metrics to personalize extended endocrine duration.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Kaur C et al. Decoding prognosis: multigene expression assays in breast cancer. Expert Rev Mol Diagn. 2026 Nov 08. doi: 10.1080/14737159.2026.2760652. PMID: 43000195.

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.

Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;285(25):2336-2347.

Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159-182.